Effects of the Peroxisome Proliferator-Activated Receptor Ligand Troglitazone in Osteosarcoma Cell Lines.
10.4055/jkoa.2005.40.5.591
- Author:
Yeung Jin KIM
1
;
Tae Kyun KIM
;
Jin Young PARK
;
Hyoung Joon KIM
;
Ji Wan LEE
Author Information
1. Department of Orthopedic Surgery, College of Medicine, Wonkwang University Hospital, Iksan, Korea. yjkim1@wonkwang.ac.kr
- Publication Type:Original Article
- Keywords:
Osteosarcoma;
Troglitazone (TRO)
- MeSH:
Actins;
Antibodies;
Apoptosis;
Blotting, Western;
Cell Cycle;
Cell Line*;
Cell Survival;
Humans;
Osteosarcoma*;
Peroxisomes*;
Trypan Blue
- From:The Journal of the Korean Orthopaedic Association
2005;40(5):591-597
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We wanted to investigate the effects of Troglitazone (TRO) on the cellular growth in two human osteosarcoma cell lines (U2OS and HOS). MATERIALS AND METHODS: Cell viability was assessed by performing trypan blue exclusion assay. FACScan analysis was performed to study the cell cycle and apoptosis. Antibodies against PTEN, tAkt, pAKt, Bcl-2, Bax, pRB, p21(Cip1), and beta-actin were used in the Western blot analysis. RESULTS: TRO inhibited the growth of both the osteosarcoma cell lines. TRO induced G0/G1 arrest in the cell cycle progression for both osteosarcoma cell lines. TRO induced the apoptosis of HOS cells, but it decreased apoptosis of the U2OS cells. TRO induced Rb dephosphorylation and the increased expression of p21(Cip1). TRO increased the PTEN and Bcl-2 expressions and it decreased the level of pAkt, pRb and Bax. CONCLUSION: The present study suggested that TRO may be used as a chemotherapeutic agent for the treatment of human OS. Yet further study is required for uncovering the precise the mechanism of TRO.
